The Future is Trippy? The FDA Starts Its First-Ever Study on Magic Mushrooms and Psychedelics

Filament Health Announces Authorization Of Phase 2 Clinical Trial Studying Botanical Psilocybin For Prolonged Grief Disorder

Filament Health Announces Transition From OTCQB To OTC Pink Limited

Filament Health Announces Voluntary Delisting From Cboe Canada